Socio Today
The prevalence of Congenital Heart Disease (CHD) remains a significant concern for the Indonesian healthcare system, as it stands as one of the primary contributors to infant mortality in the country. While the precise etiology of many congenital heart defects remains elusive to the global medical community, healthcare experts are increasingly focusing on identifiable and avoidable risk factors that occur during pregnancy. During a specialized webinar hosted by the Indonesian Pediatric Society (IDAI) on February 14, 2023, medical experts emphasized that although the direct cause-and-effect relationship for every case cannot always be established, proactive measures during the gestational period can significantly reduce the incidence of these life-threatening conditions.
Dr. Rizky Adriansyah, MKed (Sp.A), a prominent pediatric specialist and the Chairperson of the Cardiology Coordination Unit of the IDAI, highlighted that CHD represents a complex intersection of genetics and environmental influences. Speaking to an audience of healthcare professionals and the public, dr. Rizky clarified that while researchers continue to investigate the multifaceted origins of heart defects, there are at least three critical risk factors that have gained substantial traction in recent medical literature and clinical observations. These factors—maternal infections, nutritional deficiencies, and the consumption of specific medications—provide a roadmap for preventative strategies that could save thousands of newborn lives annually.
The Triad of Avoidable Risk Factors During Pregnancy
In his address, dr. Rizky identified Rubella infection, folic acid deficiency, and the use of certain medications, such as anti-seizure drugs, as the three primary factors currently under intense scrutiny. These elements interfere with the delicate process of cardiogenesis, the formation of the heart, which occurs very early in the first trimester of pregnancy, often before a woman even realizes she is expecting.
Rubella, commonly known as German measles, is a viral infection that, while mild for most individuals, can be devastating to a developing fetus. If a woman contracts Rubella during the first trimester, the virus can cross the placental barrier and disrupt the development of the fetal heart, leading to defects such as Patent Ductus Arteriosus (PDA) or pulmonary artery stenosis. The medical community stresses that the Rubella vaccine is the most effective defense against this particular risk, though it must be administered well before conception, as the vaccine itself is a live-attenuated virus not recommended during pregnancy.
The second factor, folic acid deficiency, is a well-documented contributor to both neural tube defects and congenital heart malformations. Folic acid, a B-vitamin, is essential for DNA synthesis and cell division. When maternal levels are insufficient, the complex folding and partitioning of the fetal heart can be compromised. Dr. Rizky urged expectant mothers to prioritize nutrient-dense diets and consistent supplementation as a cornerstone of prenatal care.
Thirdly, the role of maternal medication cannot be overlooked. Certain pharmaceuticals, particularly those used to manage epilepsy or chronic seizures, have been linked to an increased risk of CHD. While these medications are often necessary for the mother’s health, dr. Rizky noted the importance of medical supervision to balance the mother’s neurological stability with the safety of the developing fetus. This highlights a broader need for pre-conception counseling for women with chronic health conditions.
Debunking Myths and Broadening the Scope of Prevention
For years, public health messaging regarding CHD focused heavily on maternal lifestyle choices, specifically smoking and alcohol consumption. While these remain significant health risks that can contribute to a variety of birth defects and low birth weight, dr. Rizky pointed out a clinical paradox: many infants born with CHD come from mothers who never smoked or consumed alcohol. This reality underscores the fact that CHD is not solely a consequence of "poor choices" but is often the result of biological vulnerabilities and environmental exposures that require a more nuanced medical approach.
"Prevention is most effective during the pregnancy stage," dr. Rizky stated during the webinar. "Once the baby is born with the condition, we are no longer in the phase of prevention, but rather in the phase of management and intervention." This distinction is vital for public health policy, shifting the focus from reactive neonatal care to proactive maternal health initiatives.
The Statistical Reality of CHD in Indonesia
The urgency of addressing CHD is supported by sobering data. According to 2017 statistics from Indonesia, CHD is the second leading cause of neonatal death, accounting for approximately 17 percent of all fatalities in the first month of life, trailing only behind complications related to prematurity. This makes it a more significant threat than many infectious diseases that typically receive more public attention.
On a global scale, the World Health Organization (WHO) estimates that one out of every 100 newborns suffers from some form of CHD. Of these, approximately 25 percent are classified as "critical" CHD (CCHD). Critical cases are defined as those requiring surgical intervention or catheter-based procedures within the first year—and often the first days—of life to ensure survival. In the Indonesian context, this translates to roughly two to four cases of critical CHD for every 1,000 live births. Given Indonesia’s high birth rate, the sheer volume of children requiring specialized cardiac care is immense.
Challenges in the Indonesian Healthcare Landscape
Despite the high prevalence, dr. Rizky revealed a troubling gap in the treatment of CHD in Indonesia. Currently, less than 50 percent of CHD cases in the country receive the necessary medical or surgical intervention. This "treatment gap" is the result of a confluence of systemic factors that continue to plague the national healthcare infrastructure.
One of the primary hurdles is geographical and logistical access. Indonesia’s archipelagic nature means that specialized pediatric cardiac centers are often concentrated in major urban hubs like Jakarta or Surabaya, leaving families in remote provinces with limited options. Furthermore, there is a significant shortage of human resources; the number of pediatric cardiologists and specialized cardiac surgeons in Indonesia remains far below the ratio recommended for a population of over 270 million people.
Beyond infrastructure, there is the issue of diagnostic facilities. While advanced tools like echocardiography (heart ultrasound) are the gold standard for diagnosis, they are not universally available in all regional hospitals. However, dr. Rizky pointed out that even simpler, more affordable tools are underutilized. The lack of public awareness and, in some cases, the lack of clinical suspicion among frontline healthcare workers often lead to delayed diagnoses, which can be fatal for infants with critical defects.
Advancing Early Detection: The Role of Pulse Oximetry
To combat the high mortality rate associated with late diagnosis, the IDAI is advocating for the widespread adoption of simple screening methods. One of the most effective and cost-efficient tools identified is the pulse oximeter. This device, which measures the oxygen saturation in the blood, can be used to screen newborns for CCHD before they even leave the hospital.
Dr. Rizky explained that oximetry screening is sensitive, rapid, and non-invasive. By placing sensors on the baby’s right hand and either foot, clinicians can detect disparities in oxygen levels that indicate a heart defect. This procedure, which takes less than five minutes, can be performed by nurses or midwives in rural clinics as easily as in city hospitals.
"Delay in diagnosis remains a major problem in Indonesia," dr. Rizky emphasized. He noted that in addition to oximetry, the use of a stethoscope to detect heart murmurs remains a fundamental skill. If a murmur is detected, it must serve as an immediate red flag for further cardiac evaluation.
Clinical Manifestations and the Importance of the First 48 Hours
Recognizing the symptoms of CHD is critical for parents and primary care providers. One of the most common clinical signs is poor weight gain, as the infant’s body uses excessive energy just to maintain basic circulatory functions. In more severe or critical cases, symptoms may manifest within the first 24 to 48 hours of life, or during the first week. These can include cyanosis (a bluish tint to the skin, lips, or nails), rapid breathing, and difficulty feeding.
The medical community is pushing for a culture of "early detection" that empowers both parents and local health workers. To this end, the IDAI has supported educational initiatives such as the YouTube channel "Sehatkan Jantung Anak Indonesia" (Heal the Hearts of Indonesian Children), which provides visual guides on how to conduct screenings and recognize early warning signs.
Analysis of Implications and Future Outlook
The implications of unaddressed CHD extend beyond individual families to the broader socio-economic health of the nation. When CHD goes undiagnosed or untreated, it places a massive burden on the national health insurance system (BPJS Kesehatan) due to the high costs of emergency interventions and long-term care for chronic complications. Conversely, early detection and timely surgery allow many children with heart defects to lead full, productive lives, contributing to Indonesia’s goal of developing a "Golden Generation" by 2045.
To improve outcomes, a multi-tiered approach is necessary. First, the government must integrate CCHD screening into the standard newborn care protocol across all levels of healthcare, from village integrated health posts (Posyandu) to provincial hospitals. Second, there must be a concerted effort to increase the number of medical scholarships for pediatric cardiology and surgery to address the specialist shortage. Finally, public health campaigns must continue to emphasize the importance of prenatal nutrition and Rubella vaccination.
The insights provided by dr. Rizky Adriansyah and the IDAI serve as a call to action. While the "cause" of CHD may remain a mystery in many cases, the "solution" is increasingly clear: a combination of maternal health optimization, universal newborn screening, and the decentralization of cardiac care. By focusing on these reachable goals, Indonesia can hope to see a significant decline in neonatal mortality and a brighter future for children born with heart conditions.
